(acquired by IBM)
|$2.18 to $73.20||3487%|
|$2.35 to $24.08||925%|
|Cellstar||$1.44 to $13.50||837%|
|Iomega||$3.25 to $13.90||328%|
|Nanophase||$3.75 to $16.75||347%|
|Immunomedics||$1.44 to $29.12||1922%|
|Total Renal Care||$3.12 to $26.95||741%|
|Voxware||$ .90 to $10.31||1046%|
|Corvas||$3.00 to $23.25||675%|
|Cytogen||$2.12 to $17.50||725%|
|Verilink||$3.00 to $14.62||387%|
|GeneLabs||$2.31 to $10.72||364%|
WE CLOSED ADMA BIOLOGICS AT $6.10 FOR A 85% GAIN!
WE CLOSED CURIS, INC. AT $2.62 FOR A 80% GAIN!
WE CLOSED ANAVEX LIFE SCIENCES AT $3.95 FOR A 56% GAIN!
ALSO, WE CLOSED CATALYST PHARMACEUTICALS AT $5.24 FOR A 54% GAIN!
AND, WE CLOSED NEOS THERAPEUTICS AT $3.60 FOR A 71% GAIN!
The mid to late April Newsletter is now live and featured are EVEN TWO MORE BIOTECH picks, both trading at around $2.75. One specializes in gene therapies and has collaborations with around half dozen institutions, including MIT; while the other, a CHANNELED STOCK PICK, that worked wonders for us before, develops products to improve biodefenses.
The early to mid-May Newsletter will feature a maker of anti-infective agents that has recently had two NDAs granted by the FDA, trading at around $2.75; while the other pick develops therapies for GI diseases and is a BUY of SEVEN ANALYSTS and trades at about $3.55.
"I cannot thank you enough for your excellent newsletter... I do believe I have found a new hobby (and a well paying one, at that), thanks to you!"
— B.K. (Contractor in Saudi Arabia)